Go Pro
Andres Y. Maldonado

Andres Y. Maldonado Analyst Performance

Biotechnology Equity Research Analyst at HC Wainwright

Andres Y. Maldonado is a stock analyst at HC Wainwright focused in the medical sector, covering 24 publicly traded companies. Over the past year, Andres Y. Maldonado has issued 54 stock ratings, including buy and hold recommendations. While full access to Andres Y. Maldonado's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andres Y. Maldonado's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
54 Last 0 Years
Buy Recommendations
92.59% 50 Buy Ratings
Companies Covered
24 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy92.6%50 ratings
Hold7.4%4 ratings
Sell0.0%0 ratings

Out of 54 total stock ratings issued by Andres Y. Maldonado at HC Wainwright, the majority (92.6%) have been Buy recommendations, followed by 7.4% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
24 companies

Andres Y. Maldonado, an analyst at HC Wainwright, currently covers 24 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
23 companies
95.8%
Manufacturing
1 company
4.2%

Andres Y. Maldonado of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
20 companies
83.3%
MED - DRUGS
3 companies
12.5%
Miscellaneous
1 company
4.2%

Andres Y. Maldonado's Ratings History at HC Wainwright

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
6/29/2026Reiterated Rating$87.68$105.00Buy
Verastem, Inc. stock logo
VSTM
Verastem
6/24/2026Reiterated Rating$4.21$18.00Buy
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
6/18/2026Initiated Coverage$6.60$12.00Buy
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
6/12/2026Reiterated Rating$17.91$40.00Buy
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
6/2/2026Reiterated Rating$7.24$15.00Buy
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
5/26/2026Reiterated Rating$8.30$40.00Buy
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
5/22/2026Reiterated Rating$19.77$40.00Buy
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
5/20/2026Reiterated Rating$7.76$15.00Buy
CG Oncology, Inc. stock logo
CGON
CG Oncology
5/18/2026Reiterated Rating$66.93$100.00Buy
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
5/15/2026Boost Price Target$38.42$50.00Buy
Immunome, Inc. stock logo
IMNM
Immunome
5/13/2026Reiterated Rating$22.69$40.00Buy
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
5/8/2026Boost Price Target$46.45$65.00Buy
enGene Holdings Inc. stock logo
ENGN
enGene
5/8/2026Lower Price Target$1.72$6.00Buy
Verastem, Inc. stock logo
VSTM
Verastem
4/10/2026Reiterated Rating$5.38$18.00Buy
I-Mab stock logo
NBP
I-Mab
4/8/2026Reiterated Rating$2.48$9.00Buy
CG Oncology, Inc. stock logo
CGON
CG Oncology
4/7/2026Boost Price Target$67.55$100.00Buy
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3/30/2026Reiterated Rating$6.31$22.00Buy
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3/25/2026Reiterated Rating$52.76$53.00Neutral
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3/24/2026Upgrade$21.33$28.00Buy
I-Mab stock logo
NBP
I-Mab
3/16/2026Reiterated Rating$2.85$9.00Buy
Erasca, Inc. stock logo
ERAS
Erasca
3/13/2026Boost Price Target$14.65$20.00Buy
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3/10/2026Reiterated Rating$5.48$13.00Buy
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3/10/2026Reiterated Rating$21.33$21.50Neutral
enGene Holdings Inc. stock logo
ENGN
enGene
3/9/2026Reiterated Rating$7.38$25.00Buy
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3/3/2026Reiterated Rating$45.83$58.00Buy
CG Oncology, Inc. stock logo
CGON
CG Oncology
2/27/2026Boost Price Target$59.09$80.00Buy
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2/25/2026Lower Price Target$12.02$22.00Buy
Immunome, Inc. stock logo
IMNM
Immunome
2/12/2026Initiated Coverage$23.41$40.00Buy
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
2/10/2026Reiterated Rating$6.48$23.00Buy
Erasca, Inc. stock logo
ERAS
Erasca
1/26/2026Boost Price Target$9.96$15.00Buy
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
1/26/2026Boost Price Target$6.45$10.00Buy
Erasca, Inc. stock logo
ERAS
Erasca
1/13/2026Boost Price Target$6.23$11.00Buy
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
12/22/2025Boost Price Target$9.98$10.00Neutral
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
12/19/2025Lower Price Target$0.65$4.00Buy
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
12/3/2025Reiterated Rating$6.71$23.00Buy
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
11/24/2025Reiterated Rating$9.03$25.00Buy
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
11/19/2025Reiterated Rating$6.21$23.00Buy
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
11/13/2025Lower Price Target$1.19$7.00Buy
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
11/4/2025Upgrade$14.03$20.00Buy
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
10/27/2025Reiterated Rating$13.53$40.00Buy
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad)

Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel

See which companies control the supply chain behind this emerging tech
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
10/20/2025Reiterated Rating$19.32$40.00Buy
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
10/16/2025Initiated Coverage$15.04$40.00Buy
Merus N.V. stock logo
MRUS
Merus
9/29/2025Downgrade$93.71$97.00Neutral
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
9/29/2025Reiterated Rating$5.38$23.00Buy
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
9/23/2025Lower Price Target$32.37$44.00Buy
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
9/17/2025Reiterated Rating$10.27$40.00Buy
CG Oncology, Inc. stock logo
CGON
CG Oncology
9/15/2025Reiterated Rating$33.34$75.00Buy
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
9/10/2025Reiterated Rating$2.57$8.00Buy
enGene Holdings Inc. stock logo
ENGN
enGene
9/8/2025Reiterated Rating$5.18$25.00Buy
CG Oncology, Inc. stock logo
CGON
CG Oncology
9/5/2025Reiterated Rating$32.52$75.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
8/26/2025Initiated Coverage$30.42$70.00Buy
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
8/21/2025Reiterated Rating$4.52$7.00Buy
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
8/13/2025Reiterated Rating$7.21$22.00Buy
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
8/8/2025Lower Price Target$13.36$20.00Buy